Follow
← Back
Medicines · Interactions

Deferiprone — interactions

Other medicines, foods and herbal products can change how Deferiprone works. Everything on this page comes from Deferiprone's own FDA-approved label — the same source as the main guide.

← Back to the full Deferiprone guide

⚠ Caution: • Drugs Associated with Neutropenia or Agranulocytosis: Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count. • UGT1A6 Inhibitors: Avoid co-administration. • Polyvalent Cations: Allow at least a 4-hour interval between administration of deferiprone tablets and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

Medicines named in Deferiprone's label

Grouped the way the label groups them. Each name links to that medicine's NepalDoc guide; where the label names a class instead of a medicine, the label's words are quoted.

Drugs Associated with Neutropenia or Agranulocytosis

Avoid co-administration of deferiprone tablets with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count .

Effect of Other

Drugs on Deferiprone Tablets UDP-Glucuronosyltransferases (UGTs): Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone tablets .

Deferiprone's label names 2 medicines that NepalDoc also covers.

Their interaction pages

These medicines named in Deferiprone's label have interaction pages of their own:

Food, drink & herbs in the label

Milk & dairy

7.2 Effect of Other Drugs on Deferiprone Tablets UDP-Glucuronosyltransferases (UGTs): Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone tablets .

Read the full interactions section from Deferiprone's label

• Drugs Associated with Neutropenia or Agranulocytosis: Avoid co-administration. If co-administration is unavoidable, closely monitor the absolute neutrophil count. • UGT1A6 Inhibitors: Avoid co-administration. • Polyvalent Cations: Allow at least a 4-hour interval between administration of deferiprone tablets and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

7.1 Drugs Associated with Neutropenia or Agranulocytosis Avoid co-administration of deferiprone tablets with other drugs known to be associated with neutropenia or agranulocytosis. If co-administration is unavoidable, closely monitor the absolute neutrophil count .

7.2 Effect of Other Drugs on Deferiprone Tablets UDP-Glucuronosyltransferases (UGTs): Avoid use of UGT1A6 inhibitors (e.g., diclofenac, probenecid, or silymarin (milk thistle)) with deferiprone tablets . Polyvalent Cations: Deferiprone has the potential to bind polyvalent cations (e.g., iron, aluminum, and zinc); allow at least a 4-hour interval between deferiprone tablets and other medications (e.g., antacids), or supplements containing these polyvalent cations .

Deferiprone guide · All interaction pages · Medicines A–Z

SourcesU.S. FDA-approved label via DailyMed (label effective 1 May 2025) · National List of Essential Medicines, Nepal (2021) · U.S. labeling may differ from Nepal DDA-approved labeling and local prescribing practice.

This page summarises Deferiprone's FDA-approved label for information — it is not medical advice. Always tell your doctor or pharmacist about every medicine, supplement and herbal product you take.

Search medicines in the app / एपमा औषधि खोज्नुहोस् Find a pharmacy / फार्मेसी खोज्नुहोस्
+ Safety information

This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.

Share this Medicine
NepalDoc — Nepal's Healthcare Super-App (Beta) / नेपालको स्वास्थ्य सुपर-एप (बेटा).
Medicine information only — not medical advice. Confirm with a pharmacist or doctor.